Overview
- Humacyte reported $0.5 million in fourth-quarter revenue and $2.0 million for 2025, with product sales of $1.4 million as hospitals began ordering its Symvess graft.
- Hospital adoption signals grew with 27 Value Analysis Committee approvals, 43 more under review, and 27 hospitals placing orders, which the company said often led to re-orders.
- Executives said a new $17,000 list price has helped win VAC approvals and repeat use, noting that these committees vet new devices before hospitals can buy them and that reviews can take six to nine months.
- The company expects a pre-specified interim look at its V012 Phase 3 dialysis-access trial by early June and plans a 2026 supplemental FDA filing that combines V012 with prior V007 data.
- International and government channels expanded with a $1.475 million Saudi evaluation purchase, a marketing application filed in Israel, and U.S. Defense Department authorization to fund procurement of bioengineered vessels.